$9.51
0.32% yesterday
Nasdaq, Sep 03, 10:00 pm CET
ISIN
US0327973006
Symbol
AVXL

Anavex Life Sciences Corp. Stock price

$9.51
-1.31 12.11% 1M
+1.24 14.99% 6M
-1.23 11.45% YTD
+4.05 74.18% 1Y
+0.29 3.15% 3Y
+5.52 138.35% 5Y
+5.07 114.19% 10Y
+9.44 14,157.87% 20Y
Nasdaq, Closing price Wed, Sep 03 2025
+0.03 0.32%
ISIN
US0327973006
Symbol
AVXL
Industry

Key metrics

Basic
Market capitalization
$814.3m
Enterprise Value
$713.1m
Net debt
positive
Cash
$101.2m
Shares outstanding
85.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
9.0
Financial Health
Equity Ratio
88.7%
Return on Equity
-35.8%
ROCE
-60.4%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
- | $148.9m
EBIT
$-55.0m | $-52.9m
Net Income
$-48.2m | $-48.5m
Free Cash Flow
$-37.1m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | -
EBIT
-7.4% | -0.1%
Net Income
-16.0% | -12.8%
Free Cash Flow
-23.7%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-0.6
FCF per Share
$-0.4
Short interest
30.5%
Employees
42
Rev per Employee
$0.0
Show more

Is Anavex Life Sciences Corp. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Anavex Life Sciences Corp. Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Anavex Life Sciences Corp. forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a Anavex Life Sciences Corp. forecast:

Buy
89%
Hold
11%

Financial data from Anavex Life Sciences Corp.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 13 13
20% 20%
-
- Research and Development Expense 42 42
4% 4%
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -55 -55
7% 7%
-
Net Profit -48 -48
16% 16%
-

In millions USD.

Don't miss a Thing! We will send you all news about Anavex Life Sciences Corp. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Anavex Life Sciences Corp. Stock News

Neutral
GlobeNewsWire
one day ago
NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, ...
Neutral
GlobeNewsWire
8 days ago
NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, t...
Neutral
GlobeNewsWire
14 days ago
Pre-Treatment with blarcamesine entirely prevented Abeta-induced cognitive decline Confirmed significant biomarker-response in hippocampus NEW YORK, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophre...
More Anavex Life Sciences Corp. News

Company Profile

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Head office United States
CEO Christopher Missling
Employees 42
Founded 2004
Website www.anavex.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today